Expert Point of View: Bruce Johnson, MD, FASCO

Get Permission

“PRECISION MEDICINE is driving the most exciting and powerful advances in cancer care today, particularly in lung cancer. It’s encouraging to see that next-generation genetic testing tools can help physicians and their patients get the crucial genomic information needed to make treatment decisions, at a faster pace and lower cost than with other approaches,” said ASCO President Bruce E. Johnson, MD, FASCO, at a press briefing, where the study was presented in advance of the ASCO Annual Meeting. 

“Next-generation sequencing panels with between 50 and 400 genes yield much more information, with a cost that’s competitive or lower than standard testing,” he commented during the press briefing. ■

DISCLOSURE: Dr. Johnson has received research funding from Novartis and Toshiba and has patents and other intellectual property with royalties from Dana-Farber Cancer Institute. 

Related Articles

Decision-Analytic Model Finds Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Efficient

Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)

AN ECONOMIC model comparing different types of genetic testing in metastatic non–small cell lung cancer (NSCLC) found using next-generation sequencing to test for all known lung cancer–related gene...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.